Kezar Life Sciences, Inc.
KZR
$6.18
$0.030.49%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 0.00 |
| Cost of Revenue | 32.53M | 41.86M | 48.57M | 48.57M | 55.18M |
| Gross Profit | -32.53M | -41.86M | -48.57M | -48.57M | -55.18M |
| SG&A Expenses | 20.81M | 21.72M | 22.30M | 23.39M | 23.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 538.00K | 403.00K | 403.00K | 403.00K | 403.00K |
| Total Operating Expenses | 66.06M | 76.15M | 83.46M | 89.54M | 96.37M |
| Operating Income | -66.06M | -76.15M | -83.46M | -89.54M | -96.37M |
| Income Before Tax | -61.71M | -70.79M | -78.63M | -83.74M | -95.78M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -61.71 | -70.79 | -78.63 | -83.74 | -95.78 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.71M | -70.79M | -78.63M | -83.74M | -95.78M |
| EBIT | -66.06M | -76.15M | -83.46M | -89.54M | -96.37M |
| EBITDA | -65.08M | -75.14M | -82.43M | -88.50M | -95.30M |
| EPS Basic | -11.21 | -12.46 | -13.55 | -14.26 | -13.15 |
| Normalized Basic EPS | -7.01 | -7.79 | -8.34 | -8.78 | -7.56 |
| EPS Diluted | -11.21 | -12.46 | -13.55 | -14.26 | -13.15 |
| Normalized Diluted EPS | -7.01 | -7.79 | -8.34 | -8.78 | -7.56 |
| Average Basic Shares Outstanding | 29.24M | 29.21M | 29.19M | 29.16M | 29.13M |
| Average Diluted Shares Outstanding | 29.24M | 29.21M | 29.19M | 29.16M | 29.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |